by Paragraph: The electrocompetent cells market is estimated to be valued at US$ 2.07 Bn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Electrocompetent cells are bacterial cells that are able to take up exogenous DNA when exposed to an electric pulse or field. They are commonly used in molecular cloning and transformation experiments to produce customized gene edited clones. Some common applications of electrocompetent cells include plasmid DNA transformation and recombination cloning.
Market Dynamics:
The electrocompetent cells market is witnessing robust growth owing to increasing research and development activities in the biotechnology and pharmaceutical industry. Biotechnology and pharmaceutical companies are extensively utilizing molecular cloning techniques and transformation experiments to develop novel therapeutics and vaccines. For instance, electrocompetent cells play a vital role in the production of monoclonal antibodies, recombinant proteins, and DNA vaccines. Moreover, electrocompetent cells find wide usage in genomics and DNA sequencing research projects undertaken by academic research labs and institutes. However, availability of alternative DNA transformation techniques such as chemical and heat shock method act as a potential threat to the market growth. Nonetheless, constant product innovations to improve transformation efficiency of electrocompetent cells is expected to offer lucrative growth opportunities for market players over the forecast period.
SWOT Analysis
Strength: Electrocompetent cells allow for the efficient transformation of plasmid DNA or DNA fragments. They are commercially available and easy to use which reduces time spent on cell preparation. A wide variety of electrocompetent cell lines are offered to suit different cloning and transformation needs.
Weakness: Electrocompetent cells have low efficiency compared to chemical transformation methods. Preparing them in-house requires specialized equipment and expertise.
Opportunity: Growing applications of molecular cloning techniques in areas such as synthetic biology and gene therapy are driving demand for electrocompetent cells. New optimization of preparation protocols can help improve transformation efficiency.
Threats: Alternatives such as chemically competent and enzyme-based DNA assembly methods pose competition. Strict regulatory norms for genetically modified products impact the market.
Key Takeaways
The global Electrocompetent Cells Market Growth is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing demand for DNA recombinant technologies. The market size for 2023 is projected to reach US$ 2.07 Bn.
Regional analysis: North America currently dominates the electrocompetent cells market, owing to extensive R&D activities and increased funding for cell-based research in the region. Asia Pacific is expected to exhibit the fastest growth over the coming years due to rising life science research and biotechnology industry in China, India, and Japan.
Key players operating in the Electrocompetent Cells market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., New England Biolabs, Inc., GenScript Biotech Corporation, Lucigen Corporation, Takara Bio Inc., Delphi Genetics S.A., IBA GmbH, Scarab Genomics LLC, Zymo Research Corporation, Bioline GmbH (Meridian Bioscience), Cell Applications, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
